Bone Biologics Net Worth
Bone Biologics Net Worth Breakdown | BBLGW |
Bone Biologics Net Worth Analysis
Bone Biologics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bone Biologics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bone Biologics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bone Biologics' net worth analysis. One common approach is to calculate Bone Biologics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bone Biologics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bone Biologics' net worth. This approach calculates the present value of Bone Biologics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bone Biologics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bone Biologics' net worth. This involves comparing Bone Biologics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bone Biologics' net worth relative to its peers.
Enterprise Value |
|
To determine if Bone Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bone Biologics' net worth research are outlined below:
| Bone Biologics Corp is way too risky over 90 days horizon | |
| Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp has accumulated about 4.44 K in cash with (9.56 M) of positive cash flow from operations. | |
| Latest headline from MacroaxisInsider: Acquisition by Hankey Don of 1063830 shares of Bone Biologics subject to Rule 16b-3 |
Project Bone Biologics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.39) | (2.51) | |
| Return On Capital Employed | (3.24) | (3.08) | |
| Return On Assets | (2.39) | (2.51) | |
| Return On Equity | (3.08) | (2.93) |
When accessing Bone Biologics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bone Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bone Biologics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bone Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bone Biologics Corp. Check Bone Biologics' Beneish M Score to see the likelihood of Bone Biologics' management manipulating its earnings.
Evaluate Bone Biologics' management efficiency
The company has return on total asset (ROA) of (0.5725) % which means that it has lost $0.5725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1903) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.51 in 2024. Return On Capital Employed is likely to climb to -3.08 in 2024. At this time, Bone Biologics' Other Current Assets are fairly stable compared to the past year. Other Assets is likely to climb to 1,155 in 2024, whereas Total Current Assets are likely to drop slightly above 2.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.05 | 11.60 | |
| Net Current Asset Value | -4.2 K | -4.4 K | |
| Tangible Asset Value | -4.2 K | -4.4 K | |
| Tangible Book Value Per Share | 11.05 | 11.60 | |
| Enterprise Value Over EBITDA | (3.45) | (3.62) | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | (3.45) | (3.62) | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | -2.1 M | -2 M |
At Bone Biologics Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Return On Equity (1.19) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hankey Don 2 days ago Acquisition by Hankey Don of 1063830 shares of Bone Biologics subject to Rule 16b-3 | ||
Booth John J 3 days ago Acquisition by Booth John J of 26780 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | ||
Hankey Bret over three weeks ago Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 | ||
Heshmatpour Amir F over three months ago Acquisition by Heshmatpour Amir F of 200000 shares of Bone Biologics subject to Rule 16b-3 | ||
Hankey Don over six months ago Acquisition by Hankey Don of 553191 shares of Bone Biologics subject to Rule 16b-3 | ||
Delshad Jim over six months ago Acquisition by Delshad Jim of 26780 shares of Bone Biologics at 2.05 subject to Rule 16b-3 | ||
Deina Walsh over six months ago Acquisition by Deina Walsh of 12500 shares of Bone Biologics at 3.61 subject to Rule 16b-3 |
Bone Biologics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 21st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 18th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Bone Biologics Earnings per Share Projection vs Actual
Bone Biologics Corporate Executives
Elected by the shareholders, the Bone Biologics' board of directors comprises two types of representatives: Bone Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bone. The board's role is to monitor Bone Biologics' management team and ensure that shareholders' interests are well served. Bone Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bone Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shunichi Kuroda | CoFounder Board | Profile |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.